The global next-generation IVD market size is accounted for USD 9.69 billion in 2025 and is forecasted to hit around USD 15.61 billion by 2034, representing a CAGR of 5.45% from 2025 to 2034. The North America market size was estimated at USD 3.76 billion in 2024 and is expanding at a CAGR of 5.59% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next-Generation IVD Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next-Generation IVD Market Revenue and Volume Forecast, by Type
8.1.1. Core Laboratory Diagnostics
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Point of Care Testing
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Molecular Diagnostics
8.1.3.1. Market Revenue and Volume Forecast
9.1. Next-Generation IVD Market Revenue and Volume Forecast, by Product
9.1.1. Consumables
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Instruments
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Software
9.1.3.1. Market Revenue and Volume Forecast
10.1. Next-Generation IVD Market Revenue and Volume Forecast, by Application
10.1.1. Oncology/Cancer
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Infectious Diseases
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Diabetes
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Cardiology
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Other Applications
10.1.5.1. Market Revenue and Volume Forecast
11.1. Next-Generation IVD Market Revenue and Volume Forecast, by End-User
11.1.1. Academic & Research Institutions
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Hospitals & Clinics
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Type
12.1.2. Market Revenue and Volume Forecast, by Product
12.1.3. Market Revenue and Volume Forecast, by Application
12.1.4. Market Revenue and Volume Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Type
12.1.5.2. Market Revenue and Volume Forecast, by Product
12.1.5.3. Market Revenue and Volume Forecast, by Application
12.1.5.4. Market Revenue and Volume Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Type
12.1.6.2. Market Revenue and Volume Forecast, by Product
12.1.6.3. Market Revenue and Volume Forecast, by Application
12.1.6.4. Market Revenue and Volume Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Type
12.2.2. Market Revenue and Volume Forecast, by Product
12.2.3. Market Revenue and Volume Forecast, by Application
12.2.4. Market Revenue and Volume Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Type
12.2.5.2. Market Revenue and Volume Forecast, by Product
12.2.5.3. Market Revenue and Volume Forecast, by Application
12.2.5.4. Market Revenue and Volume Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Type
12.2.6.2. Market Revenue and Volume Forecast, by Product
12.2.6.3. Market Revenue and Volume Forecast, by Application
12.2.6.4. Market Revenue and Volume Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Type
12.2.7.2. Market Revenue and Volume Forecast, by Product
12.2.7.3. Market Revenue and Volume Forecast, by Application
12.2.7.4. Market Revenue and Volume Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Type
12.2.8.2. Market Revenue and Volume Forecast, by Product
12.2.8.3. Market Revenue and Volume Forecast, by Application
12.2.8.4. Market Revenue and Volume Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Type
12.3.2. Market Revenue and Volume Forecast, by Product
12.3.3. Market Revenue and Volume Forecast, by Application
12.3.4. Market Revenue and Volume Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Type
12.3.5.2. Market Revenue and Volume Forecast, by Product
12.3.5.3. Market Revenue and Volume Forecast, by Application
12.3.5.4. Market Revenue and Volume Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Type
12.3.6.2. Market Revenue and Volume Forecast, by Product
12.3.6.3. Market Revenue and Volume Forecast, by Application
12.3.6.4. Market Revenue and Volume Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Type
12.3.7.2. Market Revenue and Volume Forecast, by Product
12.3.7.3. Market Revenue and Volume Forecast, by Application
12.3.7.4. Market Revenue and Volume Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Type
12.3.8.2. Market Revenue and Volume Forecast, by Product
12.3.8.3. Market Revenue and Volume Forecast, by Application
12.3.8.4. Market Revenue and Volume Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Type
12.4.2. Market Revenue and Volume Forecast, by Product
12.4.3. Market Revenue and Volume Forecast, by Application
12.4.4. Market Revenue and Volume Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Type
12.4.5.2. Market Revenue and Volume Forecast, by Product
12.4.5.3. Market Revenue and Volume Forecast, by Application
12.4.5.4. Market Revenue and Volume Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Type
12.4.6.2. Market Revenue and Volume Forecast, by Product
12.4.6.3. Market Revenue and Volume Forecast, by Application
12.4.6.4. Market Revenue and Volume Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Type
12.4.7.2. Market Revenue and Volume Forecast, by Product
12.4.7.3. Market Revenue and Volume Forecast, by Application
12.4.7.4. Market Revenue and Volume Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Type
12.4.8.2. Market Revenue and Volume Forecast, by Product
12.4.8.3. Market Revenue and Volume Forecast, by Application
12.4.8.4. Market Revenue and Volume Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Type
12.5.2. Market Revenue and Volume Forecast, by Product
12.5.3. Market Revenue and Volume Forecast, by Application
12.5.4. Market Revenue and Volume Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Type
12.5.5.2. Market Revenue and Volume Forecast, by Product
12.5.5.3. Market Revenue and Volume Forecast, by Application
12.5.5.4. Market Revenue and Volume Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Type
12.5.6.2. Market Revenue and Volume Forecast, by Product
12.5.6.3. Market Revenue and Volume Forecast, by Application
12.5.6.4. Market Revenue and Volume Forecast, by End-User
13.1. Agilent Technologies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial PerTypeance
13.1.4. Recent Initiatives
13.2. bioMérieux SA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial PerTypeance
13.2.4. Recent Initiatives
13.3. Bio-Rad Laboratories, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial PerTypeance
13.3.4. Recent Initiatives
13.4. Charles River Laboratories
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial PerTypeance
13.4.4. Recent Initiatives
13.5. Danaher Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial PerTypeance
13.5.4. Recent Initiatives
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial PerTypeance
13.6.4. Recent Initiatives
13.7. Qiagen
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial PerTypeance
13.7.4. Recent Initiatives
13.8. QuidelOrtho Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial PerTypeance
13.8.4. Recent Initiatives
13.9. Quest Diagnostics Incorporated
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial PerTypeance
13.9.4. Recent Initiatives
13.10. Siemens Healthineers AG
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial PerTypeance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample